Lantern Pharma Inc.
Lantern Pharma is an AI-driven oncology biotech company dedicated to transforming cancer drug discovery and development. Utilizing its proprietary AI platform, RADR®, the company accelerates the development of targeted cancer therapies, especially for rare and unmet clinical needs. Its innovative approach includes drug repositioning, rescue of failed drugs, and precision trials to improve patient outcomes while reducing costs and timelines. Lantern Pharma actively manages a robust patent portfolio and shares scientific research through publications, posters, and collaborations.
Industries
Nr. of Employees
small (1-50)
Lantern Pharma Inc.
1920 McKinney Ave. 7th Floor, Dallas, TX 75201
Patents
Increasing cancer patient survival time by administration of dithio-containing compounds
US-11471431-B2
View DetailsCompositions and methods of use of compounds to increase cancer patient survival time
US-9320760-B2
View DetailsIncreasing cancer patient survival time by administration of dithio-containing compounds
US-9023805-B2
View DetailsCompounds and methods for reducing undesired toxicity of chemotherapeutic agents
US-7829538-B2
View Details
Increasing cancer patient survival time by administration of dithio-containing compounds
US-11471431-B2
View DetailsCompositions and methods of use of compounds to increase cancer patient survival time
US-9320760-B2
View DetailsIncreasing cancer patient survival time by administration of dithio-containing compounds
US-9023805-B2
View DetailsCompounds and methods for reducing undesired toxicity of chemotherapeutic agents
US-7829538-B2
View DetailsProducts
LP-300 in Clinical Trials
LP-300 is in Phase 2 clinical testing for never smokers with non-small cell lung cancer (NSCLC). The trial is a multicenter, open-label study evaluating LP-300 in combination with carboplatin and pemetrexed.
LP-184 in Clinical Trials
LP-184 is in Phase 1A clinical trial for advanced or metastatic solid tumors and unresectable or recurrent glioblastoma (GBM).
LP-284 in Clinical Trials
LP-284 is in Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and solid tumors.
LP-300 in Clinical Trials
LP-300 is in Phase 2 clinical testing for never smokers with non-small cell lung cancer (NSCLC). The trial is a multicenter, open-label study evaluating LP-300 in combination with carboplatin and pemetrexed.
LP-184 in Clinical Trials
LP-184 is in Phase 1A clinical trial for advanced or metastatic solid tumors and unresectable or recurrent glioblastoma (GBM).
LP-284 in Clinical Trials
LP-284 is in Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and solid tumors.
News & Updates
Lantern Pharma received FDA clearance to initiate a clinical trial targeting treatment-resistant, genomically-defined lung cancer with AI-developed LP-184.
A Phase 2 multi-center study evaluating LP-300 for never smokers with relapsed advanced primary adenocarcinoma of the lung.
Lantern Pharma's AI Platform RADR® Accelerates Oncology Drug Development
Lantern Pharma leverages AI, machine learning, and genomics to transform oncology drug discovery, aiming to reduce costs and timelines.
Lantern Pharma Collaborates with Johns Hopkins and Others on GBM and Pancreatic Cancer
Collaborations focus on advancing LP-184 in glioblastoma and pancreatic cancer using state-of-the-art models and genomic signatures.
Lantern Pharma received FDA clearance to initiate a clinical trial targeting treatment-resistant, genomically-defined lung cancer with AI-developed LP-184.
A Phase 2 multi-center study evaluating LP-300 for never smokers with relapsed advanced primary adenocarcinoma of the lung.
Lantern Pharma's AI Platform RADR® Accelerates Oncology Drug Development
Lantern Pharma leverages AI, machine learning, and genomics to transform oncology drug discovery, aiming to reduce costs and timelines.
Lantern Pharma Collaborates with Johns Hopkins and Others on GBM and Pancreatic Cancer
Collaborations focus on advancing LP-184 in glioblastoma and pancreatic cancer using state-of-the-art models and genomic signatures.